Vertigo Treatment Market By Type, By Treatment, By Distribution channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: VERTIGO TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Peripheral Vertigo
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Central Vertigo
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country

CHAPTER 5: VERTIGO TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Anticholinergics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Antihistamines
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 DrU.S.ores & Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 DrU.S.ores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
6.3.4.1 Prescription Drugs Market size and forecast, by region
6.3.4.2 OTC Drugs Market size and forecast, by region
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: VERTIGO TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by Distribution channel
7.2.4.1 North America DrU.S.ores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.4.1 Europe DrU.S.ores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.4.1 Asia-Pacific DrU.S.ores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by Distribution channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by Distribution channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.4.1 LAMEA DrU.S.ores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by Distribution channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 AstraZeneca plc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Endo Pharmaceuticals Inc
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Epic Pharma, LLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 GlaxoSmithKline plc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Hoffmann-La Roche
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Novartis AG
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sanofi
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sun Pharmaceutical Industries Ltd.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Viatris (Mylan N. V.)
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Zydus Cadila
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments

List of Tables
Table 1. Global Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 2. Vertigo Treatment Market Size, for Peripheral Vertigo, by Region, 2021-2031 ($Million)
Table 3. Vertigo Treatment Market for Peripheral Vertigo, by Country, 2021-2031 ($Million)
Table 4. Vertigo Treatment Market Size, for Central Vertigo, by Region, 2021-2031 ($Million)
Table 5. Vertigo Treatment Market for Central Vertigo, by Country, 2021-2031 ($Million)
Table 6. Global Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 7. Vertigo Treatment Market Size, for Anticholinergics, by Region, 2021-2031 ($Million)
Table 8. Vertigo Treatment Market for Anticholinergics, by Country, 2021-2031 ($Million)
Table 9. Vertigo Treatment Market Size, for Antihistamines, by Region, 2021-2031 ($Million)
Table 10. Vertigo Treatment Market for Antihistamines, by Country, 2021-2031 ($Million)
Table 11. Vertigo Treatment Market Size, for Others, by Region, 2021-2031 ($Million)
Table 12. Vertigo Treatment Market for Others, by Country, 2021-2031 ($Million)
Table 13. Global Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 14. Vertigo Treatment Market Size, for Hospital Pharmacies, by Region, 2021-2031 ($Million)
Table 15. Vertigo Treatment Market for Hospital Pharmacies, by Country, 2021-2031 ($Million)
Table 16. Vertigo Treatment Market Size, for DrU.S.ores & Retail Pharmacies, by Region, 2021-2031 ($Million)
Table 17. Vertigo Treatment Market for DrU.S.ores & Retail Pharmacies, by Country, 2021-2031 ($Million)
Table 18. Global DrU.S.ores & Retail Pharmacies Vertigo Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 19. Vertigo Treatment Market, for Prescription Drugs, by Region, 2021-2031 ($Million)
Table 20. Vertigo Treatment Market, for OTC Drugs, by Region, 2021-2031 ($Million)
Table 21. Vertigo Treatment Market Size, for Online Providers, by Region, 2021-2031 ($Million)
Table 22. Vertigo Treatment Market for Online Providers, by Country, 2021-2031 ($Million)
Table 23. Vertigo Treatment Market, by Region, 2021-2031 ($Million)
Table 24. North America Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 25. North America Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 26. North America Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 27. North America DrU.S.ores & Retail Pharmacies Vertigo Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 28. North America Vertigo Treatment Market, by Country, 2021-2031 ($Million)
Table 29. U.S. Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 30. U.S. Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 31. U.S. Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 32. Canada Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 33. Canada Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 34. Canada Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 35. Mexico Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 36. Mexico Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 37. Mexico Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 38. Europe Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 39. Europe Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 40. Europe Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 41. Europe DrU.S.ores & Retail Pharmacies Vertigo Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 42. Europe Vertigo Treatment Market, by Country, 2021-2031 ($Million)
Table 43. Germany Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 44. Germany Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 45. Germany Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 46. France Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 47. France Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 48. France Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 49. UK Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 50. UK Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 51. UK Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 52. Italy Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 53. Italy Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 54. Italy Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 55. Spain Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 56. Spain Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 57. Spain Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 58. Rest of Europe Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 59. Rest of Europe Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 60. Rest of Europe Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 61. Asia-Pacific Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 62. Asia-Pacific Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 63. Asia-Pacific Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 64. Asia-Pacific DrU.S.ores & Retail Pharmacies Vertigo Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 65. Asia-Pacific Vertigo Treatment Market, by Country, 2021-2031 ($Million)
Table 66. Japan Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 67. Japan Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 68. Japan Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 69. China Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 70. China Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 71. China Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 72. Australia Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 73. Australia Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 74. Australia Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 75. India Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 76. India Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 77. India Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 78. South Korea Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 79. South Korea Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 80. South Korea Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 81. Rest of Asia-Pacific Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 82. Rest of Asia-Pacific Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 83. Rest of Asia-Pacific Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 84. LAMEA Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 85. LAMEA Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 86. LAMEA Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 87. LAMEA DrU.S.ores & Retail Pharmacies Vertigo Treatment Market, by Prescription Type, 2021-2031 ($Million)
Table 88. LAMEA Vertigo Treatment Market, by Country, 2021-2031 ($Million)
Table 89. Brazil Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 90. Brazil Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 91. Brazil Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 92. Saudi Arabia Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 93. Saudi Arabia Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 94. Saudi Arabia Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 95. South Africa Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 96. South Africa Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 97. South Africa Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 98. Rest of LAMEA Vertigo Treatment Market, by Type, 2021-2031 ($Million)
Table 99. Rest of LAMEA Vertigo Treatment Market, by Treatment, 2021-2031 ($Million)
Table 100. Rest of LAMEA Vertigo Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 101. Astrazeneca PLC.: Company Snapshot
Table 102. Astrazeneca PLC.: Operating Segments
Table 103. Astrazeneca PLC.: Product Portfolio
Table 104. Astrazeneca PLC.: Net Sales
Table 105. Astrazeneca PLC.: Key Strategies
Table 106. Endo Pharmaceuticals Inc.: Company Snapshot
Table 107. Endo Pharmaceuticals Inc.: Operating Segments
Table 108. Endo Pharmaceuticals Inc.: Product Portfolio
Table 109. Endo Pharmaceuticals Inc.: Net Sales
Table 110. Endo Pharmaceuticals Inc.: Key Strategies
Table 111. Epic Pharma, LLC: Company Snapshot
Table 112. Epic Pharma, LLC: Operating Segments
Table 113. Epic Pharma, LLC: Product Portfolio
Table 114. Epic Pharma, LLC: Net Sales
Table 115. Epic Pharma, LLC: Key Strategies
Table 116. GlaxoSmithKline PLC.: Company Snapshot
Table 117. GlaxoSmithKline PLC.: Operating Segments
Table 118. GlaxoSmithKline PLC.: Product Portfolio
Table 119. GlaxoSmithKline PLC.: Net Sales
Table 120. GlaxoSmithKline PLC.: Key Strategies
Table 121. Hoffmann-La Roche: Company Snapshot
Table 122. Hoffmann-La Roche: Operating Segments
Table 123. Hoffmann-La Roche: Product Portfolio
Table 124. Hoffmann-La Roche: Net Sales
Table 125. Hoffmann-La Roche: Key Strategies
Table 126. Novartis AG: Company Snapshot
Table 127. Novartis AG: Operating Segments
Table 128. Novartis AG: Product Portfolio
Table 129. Novartis AG: Net Sales
Table 130. Novartis AG: Key Strategies
Table 131. Pfizer Inc.: Company Snapshot
Table 132. Pfizer Inc.: Operating Segments
Table 133. Pfizer Inc.: Product Portfolio
Table 134. Pfizer Inc.: Net Sales
Table 135. Pfizer Inc.: Key Strategies
Table 136. Sanofi: Company Snapshot
Table 137. Sanofi: Operating Segments
Table 138. Sanofi: Product Portfolio
Table 139. Sanofi: Net Sales
Table 140. Sanofi: Key Strategies
Table 141. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 142. Sun Pharmaceutical Industries Ltd.: Operating Segments
Table 143. Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 144. Sun Pharmaceutical Industries Ltd.: Net Sales
Table 145. Sun Pharmaceutical Industries Ltd.: Key Strategies
Table 146. Teva Pharmaceutical Ltd.: Company Snapshot
Table 147. Teva Pharmaceutical Ltd.: Operating Segments
Table 148. Teva Pharmaceutical Ltd.: Product Portfolio
Table 149. Teva Pharmaceutical Ltd.: Net Sales
Table 150. Teva Pharmaceutical Ltd.: Key Strategies
Table 151. Viatris (Mylan N. V.): Company Snapshot
Table 152. Viatris (Mylan N. V.): Operating Segments
Table 153. Viatris (Mylan N. V.): Product Portfolio
Table 154. Viatris (Mylan N. V.): Net Sales
Table 155. Viatris (Mylan N. V.): Key Strategies
Table 156. Zydus Cadila: Company Snapshot
Table 157. Zydus Cadila: Operating Segments
Table 158. Zydus Cadila: Product Portfolio
Table 159. Zydus Cadila: Net Sales
Table 160. Zydus Cadila: Key Strategies

List of Figures
Figure 1. Vertigo Treatment Market Segmentation
Figure 2. Vertigo Treatment Market, 2021-2031
Figure 3. Vertigo Treatment Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Vertigo Treatment Mark.:Drivers, Restraints and Opportunities
Figure 12. Vertigo Treatment Market, By Type, 2021(%)
Figure 13. Comparative Share Analysis of Peripheral Vertigo Vertigo Treatment Market, 2021-2031(%)
Figure 14. Comparative Share Analysis of Central Vertigo Vertigo Treatment Market, 2021-2031(%)
Figure 15. Vertigo Treatment Market, By Treatment, 2021(%)
Figure 16. Comparative Share Analysis of Anticholinergics Vertigo Treatment Market, 2021-2031(%)
Figure 17. Comparative Share Analysis of Antihistamines Vertigo Treatment Market, 2021-2031(%)
Figure 18. Comparative Share Analysis of Others Vertigo Treatment Market, 2021-2031(%)
Figure 19. Vertigo Treatment Market, By Distribution Channel, 2021(%)
Figure 20. Comparative Share Analysis of Hospital Pharmacies Vertigo Treatment Market, 2021-2031(%)
Figure 21. Comparative Share Analysis of Drug Stores & Retail Pharmacies Vertigo Treatment Market, 2021-2031(%)
Figure 22. Comparative Share Analysis of Online Providers Vertigo Treatment Market, 2021-2031(%)
Figure 23. Vertigo Treatment Market by Region, 2021
Figure 24. U.S. Vertigo Treatment Market, 2021-2031($Million)
Figure 25. Canada Vertigo Treatment Market, 2021-2031($Million)
Figure 26. Mexico Vertigo Treatment Market, 2021-2031($Million)
Figure 27. Germany Vertigo Treatment Market, 2021-2031($Million)
Figure 28. France Vertigo Treatment Market, 2021-2031($Million)
Figure 29. Uk Vertigo Treatment Market, 2021-2031($Million)
Figure 30. Italy Vertigo Treatment Market, 2021-2031($Million)
Figure 31. Spain Vertigo Treatment Market, 2021-2031($Million)
Figure 32. Rest of Europe Vertigo Treatment Market, 2021-2031($Million)
Figure 33. Japan Vertigo Treatment Market, 2021-2031($Million)
Figure 34. China Vertigo Treatment Market, 2021-2031($Million)
Figure 35. Australia Vertigo Treatment Market, 2021-2031($Million)
Figure 36. India Vertigo Treatment Market, 2021-2031($Million)
Figure 37. South Korea Vertigo Treatment Market, 2021-2031($Million)
Figure 38. Rest of Asia-Pacific Vertigo Treatment Market, 2021-2031($Million)
Figure 39. Brazil Vertigo Treatment Market, 2021-2031($Million)
Figure 40. Saudi Arabia Vertigo Treatment Market, 2021-2031($Million)
Figure 41. South Africa Vertigo Treatment Market, 2021-2031($Million)
Figure 42. Rest of LAMEA Vertigo Treatment Market, 2021-2031($Million)
Figure 43. Top Winning Strategies, by Year
Figure 44. Top Winning Strategies, by Development
Figure 45. Top Winning Strategies, by Company
Figure 46. Product Mapping of Top 10 Players
Figure 47. Competitive Dashboard
Figure 48. Competitive Heatmap of Top 10 Key Players
Figure 49. Astrazeneca plc.: Net Sales, ($Million)
Figure 50. Endo Pharmaceuticals In.: Net Sales, ($Million)
Figure 51. Epic Pharma, LL.: Net Sales, ($Million)
Figure 52. GlaxoSmithKline plc.: Net Sales, ($Million)
Figure 53. Hoffmann-La Roch.: Net Sales, ($Million)
Figure 54. Novartis A.: Net Sales, ($Million)
Figure 55. Pfizer Inc.: Net Sales, ($Million)
Figure 56. Sanof.: Net Sales, ($Million)
Figure 57. Sun Pharmaceutical Industries Ltd.: Net Sales, ($Million)
Figure 58. Teva Pharmaceutical Ltd.: Net Sales, ($Million)
Figure 59. Viatris (Mylan N.V..: Net Sales, ($Million)
Figure 60. Zydus Cadil.: Net Sales, ($Million)

Executive Summary

According to the report, “Vertigo Treatment Market," the vertigo treatment market size was valued at $1.3 billion in 2021, and is estimated to reach $1.9 billion by 2031, growing at a CAGR of 4.4% from 2022 to 2031.

Vertigo is a condition in which a person has sensation of whirling and loss of balance. The symptom of vertigo includes nausea and vomiting, headache, tinnitus, motion sickness, and balance problems. Furthermore, vertigo is a condition and not a disorder, therefore, at least 40% of adult experience vertigo sometimes in their life.

Factors that drive the growth of the global vertigo treatment market trends include, rise in prevalence of central vertigo in developed countries such as the U.S. and Germany, availability of medications for the vertigo treatments, increase in old age population, and increase in healthcare expenditure. In addition, increase in awareness about inner ear problems and increase in demand for vertigo treatment medications are expected to provide opportunities for the market growth. For instance, according to World Health Organization (WHO), in 2019, the number of people aged over 60 years was 1 billion. This number will increase to 1.4 billion by 2030.

Depending on type, the market is bifurcated into peripheral vertigo and central vertigo. The peripheral vertigo dominated the market in terms of revenue and is the fastest growing segment with registering CAGR of 4.7% from 2022 to 2031, due to increase in prevalence of central vertigo and rise in vertigo incidences among adults.

On the basis of treatment, the market is segmented into anticholinergics, antihistamines, and others (antibiotics, benzodiazepines, and antidepressants). The antihistamines segment exhibited the highest growth and is the fastest growing segment with registering CAGR of4.9% from 2022 to 2031, owing to low cost of OTC medications, and increased use of antihistamines which shows efficient results to treat nausea and vomiting.

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies segment was the highest revenue contributor to the vertigo treatment market share in 2021. The market growth of this segment is driven by increase in prevalence of central vertigo conditions and development of new novel drugs for the treatment of vertigo by the key players of industry. However, the online provides expected to exhibit the highest CAGR of 5.9% from 2022 to 2031, due to increase in sell of antivertigo drugs through online pharmacies.

Region-wise, in vertigo treatment market analysis, North America had the highest market share in 2021, and is expected to maintain its lead during the vertigo treatment market forecast period, owing to increase in demand for antihistamines for vertigo treatments, and strong presence of key players. Moreover, North America advances due to availability of treatments and well established healthcare infrastructure. However Asia-Pacific is expected to exhibit the highest CAGR of 5.6% during the forecast period, due to increase in awareness about vertigo conditions and its causes and initiatives taken by government for developing better healthcare.

COVID-19 is an acute disease in humans caused by a coronavirus, which is characterized mainly by fever and cough and is capable of progressing to severe symptoms and in some cases death, especially in older people and those with underlying health conditions. The COVID-19 pandemic has declined the growth of vertigo treatment industry, as the antivertigo drugs manufacturing companies are finding difficult to manufacture and sell the drugs due to disruption of supply chain and lockdown conditions. However, the vertigo treatment industry is anticipated to witness recovery in 2021 and beyond, and show stable growth for vertigo treatment market size in the coming future.

Key Findings of the Study

• Based on type, the peripheral vertigo segment held the largest market share in 2021 and is expected to remain dominant throughout the forecast period.
• By treatment, the antihistamines segment held the largest market share in 2021 and is anticipated to continue this trend during the forecast period.
• Based on distribution channel, the drug stores and retail pharmacies segment held the largest market share in 2021.
• Based on region, North America is expected to experience largest growth in 2021, and registering a CAGR of 3.6% during the forecast period.

Companies Mentioned

• AstraZeneca plc.
• Endo Pharmaceuticals Inc
• Epic Pharma, LLC
• GlaxoSmithKline plc.
• Hoffmann-La Roche
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Ltd.
• Viatris (Mylan N.V.)
• Zydus Cadila

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.